Background Several studies have reported that 2 3 of the changes in the cross-sectional area of the ridge are known to occur in the first 3 months after extraction. the loss of alveolar ridge causes problems in the aesthetic function of the subsequent implant placement as well as difficulty in securing the space. CGbio Co., Inc. has studied the alveolar socket preservation effect and safety of BMP-2 with injectable bone graft substitute (ExcelOs Inject) manufactured by mixing β -TCP and hydrogel. Aim/Hypothesis The purpose of this study was to compare the socket preservation effect and safety of Novosis-Inject (ExcelOs Inject with BMP-2) to ExcelOs Inject. Material and Methods Subjects in the clinical trial were patients aged 19 to 80 years who needed an extraction, except for the wisdom tooth. In the test group, a putty-type ExcelOs Inject (CGBio Co., Inc., Korea) with BMP-2 (Daewoong Pharmaceutical Inc., Korea) was implanted into the extraction socket and only the ExcelOs Inject was implanted in the control group. Computed tomography (CT) was performed after the procedure to establish the baseline. During the 12-weeks clinical trial period, the subjects was observed to check for any adverse events such as complications. After 12 weeks of extraction, a secondary end point CT scan was performed to evaluate the change of the extraction socket. The primary outcome measure is the change in the alveolar bone height and the secondary end point is 75, 50, 25% ESL (Extraction Socket Level) Results The primary outcome measure results in the FAS (Full Analysis Set) group showed a change in alveolar bone height (LS Mean) (-)0.50 mm in the test group (n = 41), (−)1.42 mm in the control group (n = 43) and 95% CI was 0.92. The secondary outcome measure showed a change in 75, 50 and 25% extraction socket length (LS Mean) (−) 0.63 mm, (−) 0.169 mm, (−) 0.93 mm in the test group, (−)0.70 mm, (−)1.69 mm, (−) 3.96 mm in the control group, respectively, and 95% CI was 0.46, 1.50, and 3.03 respectively. All 95% CI results were greater than 0, confirming that the test group was superior to the control group. In addition, there were no serious adverse event (AE) adverse device effect (ADE) after the clinical evaluation among the 84 patients in the safety analysis, and the difference in the incidence of adverse event between the groups was not statistically significant. Conclusions and Clinical Implications In this study, we investigated the effect of BMP-2 on the bone graft substitution of injectable ceramics (β -TCP) to improve osteoinduction and compared that in the test group (with BMP-2) and that in the control group (without BMP-2). It has been proven safe and clinically effective Novosis-Inject to use as a material for socket preservation to prevent the absorption of alveolar ridge augmentation and preserve shape after extraction.